Literature DB >> 11186310

Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers.

F Lechner1, J Sullivan, H Spiegel, D F Nixon, B Ferrari, A Davis, B Borkowsky, H Pollack, E Barnes, G Dusheiko, P Klenerman.   

Abstract

Hepatitis C virus (HCV) infection is a major public health problem, affecting an estimated 3% of the world's population, and over 10% in some countries. Infection in most cases becomes persistent, and can lead to hepatic inflammation, fibrosis and liver failure. The T lymphocyte reponse, in particular that mediated by cytotoxic T lymphocytes (CTLs), is likely to be involved in determining the outcome of infection, although its overall role is not clear. The use of major histocompatibility complex (MHC) class I peptide tetrameric complexes (tetramers) to study antiviral CTL responses has revolutionized our approach to the study of human infection. We have used a panel of MHC class I tetramers to analyse immune responses in HCV-infected individuals at various stages of disease. We find that the CTL response against HCV is vigorous in its early phases but dwindles over time both in terms of lymphocyte number and function. A number of potential explanations for this 'CTL failure' are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11186310      PMCID: PMC1692808          DOI: 10.1098/rstb.2000.0646

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  38 in total

1.  Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.

Authors:  J T Gerlach; H M Diepolder; M C Jung; N H Gruener; W W Schraut; R Zachoval; R Hoffmann; C A Schirren; T Santantonio; G R Pape
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

2.  Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study.

Authors:  J V Giorgi; Z Liu; L E Hultin; W G Cumberland; K Hennessey; R Detels
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-08

3.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

4.  Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens.

Authors:  H N Ho; L E Hultin; R T Mitsuyasu; J L Matud; M A Hausner; D Bockstoce; C C Chou; S O'Rourke; J M Taylor; J V Giorgi
Journal:  J Immunol       Date:  1993-04-01       Impact factor: 5.422

5.  Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity.

Authors:  L K Borysiewicz; S Graham; J K Hickling; P D Mason; J G Sissons
Journal:  Eur J Immunol       Date:  1988-02       Impact factor: 5.532

6.  Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif.

Authors:  A Cerny; J G McHutchison; C Pasquinelli; M E Brown; M A Brothers; B Grabscheid; P Fowler; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

7.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

8.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.

Authors:  A Carmichael; X Jin; P Sissons; L Borysiewicz
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

9.  T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay?

Authors:  R M Zinkernagel; E Haenseler; T Leist; A Cerny; H Hengartner; A Althage
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

10.  Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C.

Authors:  M A Minutello; P Pileri; D Unutmaz; S Censini; G Kuo; M Houghton; M R Brunetto; F Bonino; S Abrignani
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

View more
  10 in total

1.  Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Authors:  N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C.

Authors:  J Nattermann; G Feldmann; G Ahlenstiel; B Langhans; T Sauerbruch; U Spengler
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

3.  Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes.

Authors:  Bertrand Saunier; Miriam Triyatni; Luca Ulianich; Padma Maruvada; Paul Yen; Leonard D Kohn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 4.  Cellular immune responses against hepatitis C virus: the evidence base 2002.

Authors:  S Ward; G Lauer; R Isba; B Walker; P Klenerman
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

Review 5.  Viral escape mechanisms--escapology taught by viruses.

Authors:  M Lucas; U Karrer; A Lucas; P Klenerman
Journal:  Int J Exp Pathol       Date:  2001-10       Impact factor: 1.925

6.  Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success.

Authors:  Natalia L Komarova; Eleanor Barnes; Paul Klenerman; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

Review 7.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 8.  Ever closer to a prophylactic vaccine for HCV.

Authors:  Leo Swadling; Paul Klenerman; Eleanor Barnes
Journal:  Expert Opin Biol Ther       Date:  2013-05-07       Impact factor: 4.388

9.  Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.

Authors:  Matthias Hoffmann; Nikos Pantazis; Genevieve E Martin; Stephen Hickling; Jacob Hurst; Jodi Meyerowitz; Christian B Willberg; Nicola Robinson; Helen Brown; Martin Fisher; Sabine Kinloch; Abdel Babiker; Jonathan Weber; Nneka Nwokolo; Julie Fox; Sarah Fidler; Rodney Phillips; John Frater
Journal:  PLoS Pathog       Date:  2016-07-14       Impact factor: 6.823

10.  The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis C outcome.

Authors:  Joanna Jabłońska; Tomasz Pawłowski; Tomasz Laskus; Małgorzata Zalewska; Małgorzata Inglot; Sylwia Osowska; Karol Perlejewski; Iwona Bukowska-Ośko; Kamila Caraballo Cortes; Agnieszka Pawełczyk; Piotr Ząbek; Marek Radkowski
Journal:  BMC Infect Dis       Date:  2015-12-04       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.